Drugs / CLDN6 RNA-LPX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06940804 | Jul 2025 → Jun 2042 | extragonadal germ cell tumor, testicular germ cell tumor | BioNTech SE | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLDN6 RNA-LPX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06940804 ↗ |
| Modality | Other / unclassified | “CLDN6 ribonucleic acid-lipoplex (RNA-LPX)” NCT06940804 ↗ |
| Route | Intravenous | “IV injection” NCT06940804 ↗ |